Abstract
Heart failure is associated with symptoms of fatigue, poor quality of life and reduced exercise tolerance. One of the contributing factors to these symptoms is iron deficiency, which is present in up to one-third of patients with heart failure. The cause is complex and multifactorial, and is perceived as the initial step in developing anaemia. Randomised controlled trials have demonstrated the benefit of intravenous iron supplementation in reducing symptoms and improving exercise tolerance and quality of life, in addition to improving serum parameters and reducing inflammatory markers. Adverse effects reported in trials include pain at the injection site and injection site discolouration. No serious adverse effects were reported. There are generally no acceptable recommendations for clinical practice but intravenous iron supplementation is advocated in European and international guidelines for patients with heart failure. Routine screening for iron deficiency in this patient population is advocated, with the aim of treating any identified deficiency in a prompt manner in order to maintain functional capacity and quality of life.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
